Độ an toàn và hiệu quả của việc tiêm nội khối u tế bào T nhận diện kháng nguyên chimeric (CAR) trong ung thư vú di căn
Tóm tắt
Từ khóa
Tài liệu tham khảo
Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849
Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Beatty, 2016, Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps, Pharmacol Ther, 166, 30, 10.1016/j.pharmthera.2016.06.010
Bottaro, 1991, Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, Science, 251, 802, 10.1126/science.1846706
Ghoussoub, 1998, Expression of c-met is a strong independent prognostic factor in breast carcinoma, Cancer, 82, 1513, 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7
Jin, 2008, MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival, Cancer Res, 68, 4360, 10.1158/0008-5472.CAN-07-5960
Martens, 2006, A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo, Clin Cancer Res, 12, 6144, 10.1158/1078-0432.CCR-05-1418
Merchant, 2013, Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent, Proc Natl Acad Sci U S A, 110, E2987, 10.1073/pnas.1302725110
Pérol, 2014, Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC, Transl Lung Cancer Res, 3, 392
Beatty, 2014, Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol Res, 2, 112, 10.1158/2326-6066.CIR-13-0170
Zhao, 2010, Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res, 70, 9053, 10.1158/0008-5472.CAN-10-2880
Kummar, 2008, Phase 0 clinical trials: conceptions and misconceptions, Cancer J, 14, 133, 10.1097/PPO.0b013e318172d6f3
Tchou, 2012, Mesothelin, a novel immunotherapy target for triple negative breast cancer, Breast Cancer Res Treat, 133, 799, 10.1007/s10549-012-2018-4
Li, 2014, Mesothelin expression is associated with poor outcomes in breast cancer, Breast Cancer Res Treat, 147, 675, 10.1007/s10549-014-3077-5
Frigault, 2015, Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells, Cancer Immunol Res, 3, 356, 10.1158/2326-6066.CIR-14-0186
Crisanti, 2009, The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer, Mol Cancer Ther, 8, 2221, 10.1158/1535-7163.MCT-09-0138
Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc Natl Acad Sci U S A, 106, 3360, 10.1073/pnas.0813101106
Liu, 2017, Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation, Protein Cell, 8, 514, 10.1007/s13238-017-0422-6
Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040
Ho-Yen, 2015, The clinical and functional significance of c-Met in breast cancer: a review, Breast Cancer Res, 17, 52, 10.1186/s13058-015-0547-6
Ho-Yen, 2014, C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?, Cancer, 120, 163, 10.1002/cncr.28386
Eder, 2009, Novel therapeutic inhibitors of the c-Met signaling pathway in cancer, Clin Cancer Res, 15, 2207, 10.1158/1078-0432.CCR-08-1306
Brandes, 2005, Professional antigen-presentation function by human gammadelta T Cells, Science, 309, 264, 10.1126/science.1110267
Foster, 2007, Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12, J Immunother, 30, 506, 10.1097/CJI.0b013e318046f3b1
Corrales, 2016, The host STING pathway at the interface of cancer and immunity, J Clin Invest, 126, 2404, 10.1172/JCI86892
Davila, 2014, Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia HHS public access, Sci Transl Med, 19, 224ra25